Literature DB >> 15841310

Transcriptional and posttranscriptional regulation of the plasminogen activator system.

Yoshikuni Nagamine1, Robert L Medcalf, Pura Muñoz-Cánoves.   

Abstract

The core protein components of the plasminogen activator (PA) system are two plasminogen activators, two plasminogen activator inhibitors and a urokinase type plasminogen activator-specific cell surface receptor. Various types of biological regulation are exerted through the interplay of these components mutually and with extracellular matrix proteins and cell membrane proteins, with or without involving proteolytic activity. Reflecting these diverse biological roles, the level and activity of each component of the PA system is under the control of a variety of regulatory mechanisms. The expression level of a protein reflects the level of the corresponding mRNA, which is essentially the net result of de novo synthesis, i.e. transcription, and degradation. Many recent studies have shown that the regulation of mRNA stability is dynamic and cell specific. Accordingly, we are learning that the mRNAs of the PA system are also the subject of diverse regulatory mechanisms. In this short review, we summarize current understanding of the transcriptional and mRNA-stability regulation of the PA system.

Mesh:

Substances:

Year:  2005        PMID: 15841310     DOI: 10.1160/TH04-12-0814

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  22 in total

1.  Glycodelin-A protein interacts with Siglec-6 protein to suppress trophoblast invasiveness by down-regulating extracellular signal-regulated kinase (ERK)/c-Jun signaling pathway.

Authors:  Kevin K W Lam; Philip C N Chiu; Cheuk-Lun Lee; Ronald T K Pang; Carmen O N Leung; Hannu Koistinen; Markku Seppala; Pak-Chung Ho; William S B Yeung
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

2.  Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome.

Authors:  Isabell D Witzel; Karin Milde-Langosch; Ralph M Wirtz; Claudia Roth; Maike Ihnen; Sven Mahner; Christine Zu Eulenburg; Fritz Jänicke; Volkmar Müller
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-04       Impact factor: 4.553

3.  Modulation of urokinase plasminogen activator system by poly(ADP-ribose)polymerase-1 inhibition.

Authors:  Josip Madunić; Mariastefania Antica; Petra Cvjetko; Lidija Požgaj; Maja Matulić
Journal:  Cytotechnology       Date:  2014-12-04       Impact factor: 2.058

4.  Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.

Authors:  Lauren Bryan; Barbara S Paugh; Dmitri Kapitonov; Katarzyna M Wilczynska; Silvina M Alvarez; Sandeep K Singh; Sheldon Milstien; Sarah Spiegel; Tomasz Kordula
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

5.  Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes.

Authors:  Maria Diamandis; Andrew D Paterson; Johanna M Rommens; D Kika Veljkovic; Jessica Blavignac; Dennis E Bulman; John S Waye; Francine Derome; Georges E Rivard; Catherine P M Hayward
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

6.  EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCdelta, and sphingosine kinase 1 in glioblastoma cells.

Authors:  Barbara S Paugh; Steven W Paugh; Lauren Bryan; Dmitri Kapitonov; Katarzyna M Wilczynska; Sunita M Gopalan; Hanna Rokita; Sheldon Milstien; Sarah Spiegel; Tomasz Kordula
Journal:  FASEB J       Date:  2007-09-12       Impact factor: 5.191

7.  Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation.

Authors:  D Kika Veljkovic; Georges E Rivard; Maria Diamandis; Jessica Blavignac; Elisabeth M Cramer-Bordé; Catherine P M Hayward
Journal:  Blood       Date:  2008-11-24       Impact factor: 22.113

8.  Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.

Authors:  C Ostheimer; C Evers; M Bache; T Reese; D Vordermark
Journal:  Strahlenther Onkol       Date:  2018-01-16       Impact factor: 3.621

9.  Induction of brain microvascular endothelial cell urokinase expression by Cryptococcus neoformans facilitates blood-brain barrier invasion.

Authors:  Jamal Stie; Deborah Fox
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

10.  Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients.

Authors:  Matthias Kotzsch; Viktor Magdolen; Thomas Greither; Matthias Kappler; Matthias Bache; Christine Lautenschläger; Susanne Füssel; Alexander W Eckert; Thomas Luther; Gustavo Baretton; Peter Würl; Helge Taubert
Journal:  BMC Cancer       Date:  2011-06-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.